THAR vs. PTPI, CING, ARTL, LGVN, XCUR, LIPO, NEXI, GNPX, ATXI, and SEEL
Should you be buying Tharimmune stock or one of its competitors? The main competitors of Tharimmune include Petros Pharmaceuticals (PTPI), Cingulate (CING), Artelo Biosciences (ARTL), Longeveron (LGVN), Exicure (XCUR), Lipella Pharmaceuticals (LIPO), NexImmune (NEXI), Genprex (GNPX), Avenue Therapeutics (ATXI), and Seelos Therapeutics (SEEL). These companies are all part of the "pharmaceutical preparations" industry.
Tharimmune (NASDAQ:THAR) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.
Tharimmune has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500.
In the previous week, Petros Pharmaceuticals had 1 more articles in the media than Tharimmune. MarketBeat recorded 3 mentions for Petros Pharmaceuticals and 2 mentions for Tharimmune. Petros Pharmaceuticals' average media sentiment score of 1.00 beat Tharimmune's score of -0.33 indicating that Petros Pharmaceuticals is being referred to more favorably in the news media.
Petros Pharmaceuticals received 1 more outperform votes than Tharimmune when rated by MarketBeat users.
1.2% of Tharimmune shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 2.4% of Tharimmune shares are owned by insiders. Comparatively, 36.4% of Petros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Tharimmune has a net margin of 0.00% compared to Petros Pharmaceuticals' net margin of -181.87%. Petros Pharmaceuticals' return on equity of -68.90% beat Tharimmune's return on equity.
Petros Pharmaceuticals has a consensus target price of $4.00, suggesting a potential upside of 525.10%. Given Petros Pharmaceuticals' higher probable upside, analysts clearly believe Petros Pharmaceuticals is more favorable than Tharimmune.
Petros Pharmaceuticals has higher revenue and earnings than Tharimmune. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.
Summary
Petros Pharmaceuticals beats Tharimmune on 13 of the 15 factors compared between the two stocks.
Get Tharimmune News Delivered to You Automatically
Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding THAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tharimmune Competitors List
Related Companies and Tools
